• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line).
  
• Mutation; HGNC; HGNC:3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line).
  

PubMed=26735014; DOI=10.1038/nature16508; PMCID=PMC4854653
Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P., Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E., Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C., Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K., Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E., Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S., Meyer C.A., Bradner J.E., Polyak K.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature 529:413-417(2016)

PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027; PMCID=PMC7306005
Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B., Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K., Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S., Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W., McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.-D., Michel B., Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S., Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F., Polyak K.
Synthetic lethal and resistance interactions with BET bromodomain inhibitors in triple-negative breast cancer.
Mol. Cell 78:1096-1113.e8(2020)